Currently, multiple immunotherapies (e.g., modulators of PD-1/PD-L1, upregulators of tumor-associated macrophages, etc.)are also being tested for NSCLC in combination with various drugs [43,44,45]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.